相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。High-Affinity GD2-Specific CAR T Cells Induce Fatal Encephalitis in a Preclinical Neuroblastoma Model
Sarah A. Richman et al.
CANCER IMMUNOLOGY RESEARCH (2018)
Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
Dal Fukurnura et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Improving the Efficiency of Vγ9Vδ2 T Cell Immunotherapy in Cancer
Timm Hoeres et al.
FRONTIERS IN IMMUNOLOGY (2018)
The NKG2D/NKG2DL Axis in the Crosstalk Between Lymphoid and Myeloid Cells in Health and Disease
Ana Stojanovic et al.
FRONTIERS IN IMMUNOLOGY (2018)
A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children's Oncology Group Study ANBL0931 (vol 9, 1355, 2018)
M. Fevzi Ozkaynak et al.
FRONTIERS IN IMMUNOLOGY (2018)
Advances in the translational genomics of neuroblastoma: From improving risk stratification and revealing novel biology to identifying actionable genomic alterations
Kristopher R. Bosse et al.
CANCER (2016)
Effective combination treatment of GD2-expressing neuroblastoma and Ewing's sarcoma using anti-GD2 ch14.18/CHO antibody with Vγ9Vδ2+γδT cells
Jonathan P. H. Fisher et al.
ONCOIMMUNOLOGY (2016)
Bioengineering and serum free expansion of blood-derived γδT cells
Kathryn S. Sutton et al.
CYTOTHERAPY (2016)
Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy
Christina Pfirschke et al.
IMMUNITY (2016)
Three cases of congenital dysfibrinogenemia in unrelated Chinese families: heterozygous missense mutation in fibrinogen alpha chain Argl6His
Meiling Luo et al.
MEDICINE (2016)
Heterogeneous yet stable Vδ2(+) T-cell profiles define distinct cytotoxic effector potentials in healthy human individuals
Paul L. Ryan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
The prognostic landscape of genes and infiltrating immune cells across human cancers
Andrew J. Gentles et al.
NATURE MEDICINE (2015)
Engineering anti-GD2 monoclonal antibodies for cancer immunotherapy
Mahiuddin Ahmed et al.
FEBS LETTERS (2014)
gamma delta T Cells and Their Potential for Immunotherapy
Yan-Ling Wu et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES (2014)
Phase I Trial of a Novel Anti-GD2 Monoclonal Antibody, Hu14.18K322A, Designed to Decrease Toxicity in Children With Refractory or Recurrent Neuroblastoma
Fariba Navid et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
T-Cell and NK-Cell Infiltration into Solid Tumors: A Key Limiting Factor for Efficacious Cancer Immunotherapy
Ignacio Melero et al.
CANCER DISCOVERY (2014)
Clinical applications of gamma delta T cells with multivalent immunity
Drew C. Deniger et al.
FRONTIERS IN IMMUNOLOGY (2014)
Dacarbazine-Mediated Upregulation of NKG2D Ligands on Tumor Cells Activates NK and CD8 T Cells and Restrains Melanoma Growth
Alice Hervieu et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2013)
Children's Oncology Group's 2013 blueprint for research: Neuroblastoma
Julie R. Park et al.
PEDIATRIC BLOOD & CANCER (2013)
Engineered Drug Resistant γδ T Cells Kill Glioblastoma Cell Lines during a Chemotherapy Challenge: A Strategy for Combining Chemo- and Immunotherapy
Lawrence S. Lamb et al.
PLOS ONE (2013)
Six-of-the-best: unique contributions of γδ T cells to immunology
Pierre Vantourout et al.
NATURE REVIEWS IMMUNOLOGY (2013)
Treatment of a Solid Tumor Using Engineered Drug-Resistant Immunocompetent Cells and Cytotoxic Chemotherapy
Anindya Dasgupta et al.
HUMAN GENE THERAPY (2012)
Understanding the complexity of γδ T-cell subsets in mouse and human
Dick J. Pang et al.
IMMUNOLOGY (2012)
Histone deacetylase inhibitors enhance expression of NKG2D ligands in Ewing sarcoma and sensitize for natural killer cell-mediated cytolysis
Dagmar Berghuis et al.
CLINICAL SARCOMA RESEARCH (2012)
Naive, effector and memory CD8 T-cell trafficking: parallels and distinctions
Jeffrey C. Nolz et al.
IMMUNOTHERAPY (2011)
Revisiting human natural killer cell subset function revealed cytolytic CD56dimCD16+ NK cells as rapid producers of abundant IFN-γ on activation
Andrea De Maria et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Autophagy-Dependent Anticancer Immune Responses Induced by Chemotherapeutic Agents in Mice
Mickael Michaud et al.
SCIENCE (2011)
Engineered drug-resistant immunocompetent cells enhance tumor cell killing during a chemotherapy challenge
Anindya Dasgupta et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2010)
5-Fluorouracil Selectively Kills Tumor-Associated Myeloid-Derived Suppressor Cells Resulting in Enhanced T Cell-Dependent Antitumor Immunity
Julie Vincent et al.
CANCER RESEARCH (2010)
Expansion of regulatory T cells via IL-2/anti-IL-2 mAb complexes suppresses experimental myasthenia
Ruolan Liu et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2010)
Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice
Rupal Ramakrishnan et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
Enhanced Tumor Trafficking of GD2 Chimeric Antigen Receptor T Cells by Expression of the Chemokine Receptor CCR2b
John A. Craddock et al.
JOURNAL OF IMMUNOTHERAPY (2010)
Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma.
Alice L. Yu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Monoclonal antibodies: versatile platforms for cancer immunotherapy
Louis M. Weiner et al.
NATURE REVIEWS IMMUNOLOGY (2010)
ATM-ATR-dependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK-cell susceptibility and is associated with a senescent phenotype
Alessandra Soriani et al.
BLOOD (2009)
The GD2-specific 14G2a monoclonal antibody induces apoptosis and enhances cytotoxicity of chemotherapeutic drugs in IMR-32 human neuroblastoma cells
Aleksandra Kowalczyk et al.
CANCER LETTERS (2009)
Phase I Study of ch14.18 With Granulocyte-Macrophage Colony-Stimulating Factor and Interleukin-2 in Children With Neuroblastoma After Autologous Bone Marrow Transplantation or Stem-Cell Rescue: A Report From the Children's Oncology Group
Andrew L. Gilman et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Long-Term Results for Children With High-Risk Neuroblastoma Treated on a Randomized Trial of Myeloablative Therapy Followed by 13-cis-Retinoic Acid: A Children's Oncology Group Study
Katherine K. Matthay et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Long-term Outcomes in Survivors of Neuroblastoma: A Report From the Childhood Cancer Survivor Study
Caroline Laverdiere et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)
Impact of Chemotherapy Dose Intensity on Cancer Patient Outcomes
Gary H. Lyman
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2009)
Regulatory T cells and immune tolerance
Shimon Sakaguchi et al.
CELL (2008)
Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma
Martin A. Pule et al.
NATURE MEDICINE (2008)
Metronomic cyclophosphamide regimen selectively depletes CD4+ CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients
Francois Ghiringhelli et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2007)
Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O-6-methylguanine
W. P. Roos et al.
ONCOGENE (2007)
Hurdles to lymphocyte trafficking in the tumor microenvironment: Implications for effective immunotherapy
Daniel T. Fisher et al.
IMMUNOLOGICAL INVESTIGATIONS (2006)
The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor
S Gasser et al.
NATURE (2005)
Inhibition of CD4+25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide
MEC Lutsiak et al.
BLOOD (2005)
CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative
F Ghiringhelli et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2004)
T cell antigen receptor engagement and specificity in the recognition of stress-inducible MHC class I-related chains by human epithelial γδ T cells
J Wu et al.
JOURNAL OF IMMUNOLOGY (2002)